Back to Search
WILLIAM PAO, MD, PHD
MD, PHD
Medical Oncology Physician
NPI: 1700857604Individual
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
44440(TN)
Research & Publications (20)
Use of epidermal growth factor receptor/Kirsten rat sarcoma 2 viral oncogene homolog mutation testing to define clonal relationships among multiple lung adenocarcinomas: comparison with clinical guidelines.
PMID 19376842·Chest·2010
4-observational
PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR.
PMID 19351834·Cancer Res·2009
8-other
EML4-ALK: honing in on a new target in non-small-cell lung cancer.
PMID 19667260·J Clin Oncol·2009
8-other
An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors.
PMID 19525976·Oncogene·2009
8-other
Genomic and mutational profiling to assess clonal relationships between multiple non-small cell lung cancers.
PMID 19671847·Clin Cancer Res·2009
8-other
Morphologic features of adenocarcinoma of the lung predictive of response to the epidermal growth factor receptor kinase inhibitors erlotinib and gefitinib.
PMID 19260752·Arch Pathol Lab Med·2009
8-other
The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers.
PMID 19478061·Proc Natl Acad Sci U S A·2009
8-other
Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.
PMID 18632602·Cancer Res·2008
7-preclinical
Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma.
PMID 18794081·Clin Cancer Res·2008
8-other
Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib.
PMID 18349398·J Clin Oncol·2008
3-trial
Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.
PMID 18981003·Clin Cancer Res·2008
8-other
EGFR mutant lung adenocarcinomas in patients with germline BRCA mutations.
PMID 18594331·J Thorac Oncol·2008
5-case
Constitutive activation of Raf-1 induces glioma formation in mice.
PMID 18472967·Neoplasia·2008
7-preclinical
Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy.
PMID 18509184·J Clin Oncol·2008
3-trial
EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression.
PMID 18403609·J Mol Diagn·2008
8-other
Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma.
PMID 19010870·Clin Cancer Res·2008
5-case
Genetic predictors of MEK dependence in non-small cell lung cancer.
PMID 19010912·Cancer Res·2008
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 2220 PIERCE AVE, 777 PRESTON RESEARCH BUILDING
NASHVILLE, TN 37232 - Phone
- (615) 936-3831
Quick Facts
- NPI
- 1700857604
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile